DE69114519D1 - Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen. - Google Patents

Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen.

Info

Publication number
DE69114519D1
DE69114519D1 DE69114519T DE69114519T DE69114519D1 DE 69114519 D1 DE69114519 D1 DE 69114519D1 DE 69114519 T DE69114519 T DE 69114519T DE 69114519 T DE69114519 T DE 69114519T DE 69114519 D1 DE69114519 D1 DE 69114519D1
Authority
DE
Germany
Prior art keywords
vaccine
immune response
immunogenes
increase
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69114519T
Other languages
English (en)
Other versions
DE69114519T2 (de
Inventor
Edward J Rozhon
John O'connell
Stuart Cox
Michael Hayre
Jerome Schwartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69114519D1 publication Critical patent/DE69114519D1/de
Application granted granted Critical
Publication of DE69114519T2 publication Critical patent/DE69114519T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE69114519T 1990-12-19 1991-12-17 Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen. Expired - Fee Related DE69114519T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62980090A 1990-12-19 1990-12-19
PCT/US1991/009167 WO1992011030A1 (en) 1990-12-19 1991-12-17 Use of il-4 to enhance immune response to immunogens in vaccines

Publications (2)

Publication Number Publication Date
DE69114519D1 true DE69114519D1 (de) 1995-12-14
DE69114519T2 DE69114519T2 (de) 1996-04-04

Family

ID=24524543

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69114519T Expired - Fee Related DE69114519T2 (de) 1990-12-19 1991-12-17 Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen.

Country Status (20)

Country Link
EP (1) EP0563254B1 (de)
JP (1) JPH06503830A (de)
CN (1) CN1063227A (de)
AT (1) ATE129900T1 (de)
AU (1) AU9161591A (de)
CA (1) CA2098726A1 (de)
CZ (1) CZ119993A3 (de)
DE (1) DE69114519T2 (de)
DK (1) DK0563254T3 (de)
ES (1) ES2079851T3 (de)
FI (1) FI932759A (de)
GR (1) GR3018820T3 (de)
HU (1) HUT68529A (de)
IE (1) IE70453B1 (de)
IL (1) IL100402A0 (de)
OA (1) OA09863A (de)
PT (1) PT99838A (de)
SK (1) SK59393A3 (de)
WO (1) WO1992011030A1 (de)
ZA (1) ZA919907B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US7449186B1 (en) * 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
DE69310182T2 (de) * 1992-08-10 1997-12-04 Us Gov Health & Human Serv Interleukin-4 stimulierter t-lymphozyten-zelltod
WO1994028871A1 (en) * 1993-06-07 1994-12-22 Endocon, Inc. Implant stimulated cellular immunity
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
ZA875681B (en) * 1986-08-01 1988-04-27 Commw Scient Ind Res Org Recombinant vaccine
WO1991001143A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Stable vaccine compositions containing interleukins
EP0521916B1 (de) * 1990-03-21 1996-01-17 Schering Corporation Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen-herausforderungen

Also Published As

Publication number Publication date
GR3018820T3 (en) 1996-04-30
IL100402A0 (en) 1992-09-06
WO1992011030A1 (en) 1992-07-09
AU9161591A (en) 1992-07-22
CN1063227A (zh) 1992-08-05
EP0563254A1 (de) 1993-10-06
ES2079851T3 (es) 1996-01-16
JPH06503830A (ja) 1994-04-28
CA2098726A1 (en) 1992-06-20
IE70453B1 (en) 1996-11-27
IE914436A1 (en) 1992-07-01
OA09863A (en) 1994-08-15
CZ119993A3 (en) 1994-02-16
ZA919907B (en) 1992-08-26
HUT68529A (en) 1995-06-28
ATE129900T1 (de) 1995-11-15
DK0563254T3 (da) 1996-02-12
DE69114519T2 (de) 1996-04-04
SK59393A3 (en) 1994-03-09
EP0563254B1 (de) 1995-11-08
FI932759A0 (fi) 1993-06-16
FI932759A (fi) 1993-06-16
HU9301797D0 (en) 1993-10-28
PT99838A (pt) 1992-12-31

Similar Documents

Publication Publication Date Title
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
NO883896L (no) Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.
ES2149776T3 (es) Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
AU4951196A (en) Vaccines for plague
ATE103297T1 (de) Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea.
DE69114519D1 (de) Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen.
DE69122364D1 (de) Verwendung von (S)-Isofluran und (S)-Desfluran zur Anästhesie sowie entsprechende Arzneimittelzubereitungen
FR2746110B1 (fr) Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
ATE133074T1 (de) Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen
DE69633233D1 (de) Multivalenter impstoff gegen bovines coronavirus und methode zur behandlung einer infektion mit bovinem coronavirus
ATE229981T1 (de) Glykolisierte cytokine
EP0048422A3 (de) Haare von Pseudomonas-Aeruginosa und deren Verwendung als Impfstoffe gegen infektiöse P.Aeruginosa
NO892015D0 (no) Fremgangsmaate for fremstilling av et legemiddel.
ATE83381T1 (de) Verwendung von rekombiniertem menschlichem alpha- interferon zur herstellung eines arzneimittels zur behandlung des aids-virus.
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
DE69123252T2 (de) Kreuzreaktive immunisierung gegen influenza
RU93043610A (ru) Фармацевтическая композиция для усиления первичной иммуно-реакции у млекопитающих, способ усиления первичной иммуно-реакции и применение интерлейкина-4 для усиления первичной иммуно-реакции у млекопитающих, набор лекарственных средств

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee